February 8, 2023 4:56pm
And consider how to control your portfolio, RMi relates and proposes following closer the drift of the sector and market by waiting for Q4 earnings to play-out
News: Avrobio (AVRO) popped +$0.8175 (+93.7%) to $1.69 with 39.32 M shares traded – offering dilution question and shareholder notification?
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -207.68 points (- 0.61%); the S&P closed DOWN -46.14 points (-1.11%) while the Nasdaq closed DOWN -203.27 points (-1.68%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies
Indexes slid Wednesday as investors returned focus to corporate earnings and the outlook for interest rates after Fed Chair Powell signaled more hikes may be needed than markets are pricing in.
Our sector earnings for Q4 start on 2/16.
A quote to consider,” The move lower marks a turn from Tuesday’s rally, which was mainly driven by Fed Chair Jerome Powell’s remarks that inflation has started easing. His comments reiterated those given at his press conference last week, further bolstering investor hopes that the central bank will soon pause or pivot on interest rate hikes.” <CNBC>
Wednesday’s …RegMed Investors’ (RMi) pre-open: a bumpy road of too many unknowns and a weak aftermarket and pre-open indications.” … https://www.regmedinvestors.com/articles/12823
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences
- Wednesday’s advance/decline line opened negative at 9 up/ 24 down and 2 flats, stayed negative with 6 up/ 28 down and 1 flat at the mid-day, ending with a negative close of 4/31 and 0 flat
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
Wednesday, the IBB was down -2.19% and the XBI was down -3.47%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was up +0.99. points or +5.31% at 19.65
Closing Down (10 of 31):
- Beam Therapeutics (BEAM -$3.62 after Tuesday’s -$0.38 after Monday’s -$0.34),
- Alnylam Pharmaceuticals (ALNY -$3.20 after Tuesday’s -$3.30 and Monday’s -$9.23),
- CRISPR Therapeutics (CRSP -$2.28 after Tuesday’s +$0.31 and Monday’s +$0.24),
- Ultragenyx (RARE -$2.16 after Tuesday’s +$1.87 and Monday’s +$0.21),
- Vericel (VCEL -$1.83 after Tuesday’s +$0.70 and Monday’s -$0.46),
- Sage Therapeutics (SAGE -$1.76 after Tuesday’s +$0.92 and Monday’s +$1.56),
- Intellia Therapeutics (NTLA -$1.71 after Tuesday’s +$1.06 and Monday’s +$0.62),
- Ionis Pharmaceuticals (IONS -$1.65 after Tuesday’s +$0.44 and Monday’s -$0.42),
- Verve therapeutics (VERV -$1.56),
- Regenxbio (RGNX -$0.91 after Tuesday’s +$0.74 and Monday’s -$0.49),
Closing Up (4 of 4):
- Avrobio (AVRO +$0.8175 after Tuesday’s -$0.05),
- BioLife Solutions (BLFS +$0.42 after Tuesday’s -$1.52),
- Mesoblast (MESO +$0.07),
- Bellicum Pharmaceuticals (BLCM +$0.05 after Tuesday’s -$0.07 and Monday’s +$0.12),
Q1/23 – February
- Wednesday closed negative with 4 incliner, 31 decliners and 0 flat
The BOTTOM LINE: I try to keep it simple … and short!
Did this quote “spook” markets on Wednesday, Fed Governor Christopher Waller said” inflation seems poised to continue slowing this year but the U.S. central bank's battle to reach its 2% target "might be a long fight" with monetary policy kept tighter for longer than anticipated.”
As investors have been concerned about how aggressive the Fed's actions may be this year following last Friday's surprisingly strong U.S. jobs report.
Sentiment is governed by electronic trading and algorithms. Past upsides were profited upon and will be continued focus on SELLING-into-Strength before earnings hit.
Upcoming Q4 earnings reporting will present challenges to share pricing.
· Sage Therapeutics (SAGE) 2/16 – Thursday
· Ionis Pharmaceuticals (IONS) 2/22 – Wednesday
· Alnylam Pharmaceuticals (ALNY) 2/23 - Thursday
If you thought of buying on weakness, you might be jumping onto a sinking ship.
Attention remains… laser-focused on week’s busy economic calendar; there’s still a bit of hesitation in front of inflation data to really see the reality of the markets and cell and gene therapy sector ability or capacity to move upward.
There are VERY clear losers today … Beam therapeutics (BEAM), Alnylam Pharmaceuticals (ALNY) – again and CRISPR Therapeutics (CRSP)
With winners … Avrobio (AVRO), BioLife Solutions (BLFS) and Mesoblast (MESO)
Avrobio (AVRO) closed up +$0.81 with 39.32 M shares traded after Tuesday’s -$0.06 to $0.86 with 201,388 shares traded <3-month average = 352,521 shares>
Has AVRO executed offering with our shareholder notification?
STILL, just another “screw-job” of investors! < Read, SELL and Weep - see hyperlink below>
Avrobio (AVRO) files S-3 (Registration Statement) for offering with draft prospectus by Cowen … https://investors.avrobio.com/node/9116/html
· Also, RA Capital has sold its position in the company – a sign of dissatisfaction!
· While, President, CEO and director Geoff Mackay carries home a HUGE salary of $754.39 K per year?
Biostage (OTCQB: BSTG)
Tuesday closed down -$0.01 with 148 shares traded on Wednesday after Tuesday’s flat on Monday and Friday with 90 shares traded after Thursday’s flat with 0 shares traded, Wednesday’s +$0.28 with 467 shares traded, Tuesday’s -$0.73 with 3,710 shares traded after Monday closed down -$0.03 with772 shares traded and last Friday’s flat with 1,695 shares traded. <3-month average volume = 1,285 shares>
· BSTG has “pulled” its proposed offering … “Withdrawal of Registration Statement on Form S-1 (File No. 333-265741)”
· This IND – now almost 4 years old without a clinical trial that will last 3-5 years for ADULT patients before BSTG can EVEN consider a pediatric venue!
Question; is OTCQB: BSTG a Ponzi scheme (the pump/promote buy and sell agenda) as shares are bought to replace those sold??
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
